Application 022233
- Type
- NDA
- Sponsor
- HELSINN HLTHCARE
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ALOXI | PALONOSETRON HYDROCHLORIDE | CAPSULE;ORAL | EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | Yes | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N022233-001 | ALOXI | PALONOSETRON HYDROCHLORIDE | EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE / ORAL | RLD | 2008-08-22 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N022233-001 | ALOXI | EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE / ORAL | RLD | 2008-08-22 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Palonosetron | PALONOSETRON HYDROCHLORIDE | BLuePoint Laboratories | bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea | 2026-07-06 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Eugia US LLC | 42e2d437-0712-4e9c-9c2a-00093c406d62 | 2025-10-30 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Apotex Corp. | 4af600d1-0ab1-41c5-af2f-9dc24cf3c90e | 2025-06-09 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Apotex Corp. | 903d7aba-277e-6d28-4fee-fd2d605ab6a9 | 2025-01-02 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Avenacy, Inc. | 0063b66a-a71b-473c-97b8-7c59f2a5b18e | 2024-05-15 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Sandoz Inc | 5bfb3984-2b47-4e06-9bbb-d055ebc376c8 | 2024-02-05 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Sandoz Inc | aff1505c-8d34-46e6-9559-c5b112887875 | 2024-02-05 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | 11bb07b2-6530-45ab-a916-ba9dd3107fc3 | 2023-08-17 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| palonosetron hydrochloride | PALONOSETRON HYDROCHLORIDE | Cipla USA Inc. | 37e7ef89-fd77-44e0-9271-ae91f8822603 | 2022-01-13 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Qilu Pharmaceutical Co., Ltd. | 633abdc2-a942-4eb2-a0f8-f9f4e727211e | 2021-10-18 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Baxter Healthcare Corporation | 0f3bfe3d-75c8-42eb-84be-570f8e251fdd | 2020-09-15 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Mylan Institutional LLC | 0a781796-bb74-4c5f-8d26-9ce520b818f7 | 2020-06-09 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| palonosetron hydrochloride | PALONOSETRON HYDROCHLORIDE | Sagent Pharmaceuticals | 6e60d03d-eae6-4924-a507-e77ea077c1ab | 2020-04-28 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Teva Parenteral Medicines, Inc. | 911783eb-91a8-4ef4-bd6f-809211e207d6 | 2020-04-01 | Warnings, Adverse reactions | PALONOSETRON HYDROCHLORIDE |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 69639-104 | ALOXI | palonosetron hydrochloride | Helsinn Therapeutics (U.S.), Inc. | NDA | Current |